India Pharma Webinar: COVID-19 Impact, Dealing With Business Continuity
Informa Markets’ recent webinar on COVID-19 and its impact on the Indian pharmaceutical industry deliberated a range of burning issues across the sector’s spectrum of activities, including efforts to stem India’s vulnerable dependency on active pharmaceutical ingredients imported from China, current trends for the excipients and pharma machinery segments and how industry is handling demand-supply disruptions in these challenging times.
You may also be interested in...
Sun Pharma says that the first quarter of 2021 will likely be challenging across the industry with a lull in new prescriptions in India, especially in the acute and semi-chronic segments. But the firm remains upbeat about its lead psoriasis asset Ilumya, which has inched close to the $100m sales mark in its first full year of commercialization.
The new US public benefit pharma manufacturing firm Phlow has received significant federal funding in a bid to improve domestic supply security. Scrip speaks to prominent executives in India's industry over whether this model, if widely replicated, could put at risk the clout and market access plans of the Indian generic industry, a major supplier to the US market.
Dr Reddy’s enjoyed a strong showing in Europe in the fiscal fourth quarter amid a string of launches and a ramp-up in France, Italy and Spain, with the Indian firm anticipating continued momentum in the region by leveraging its global portfolio. The firm’s China growth strategy is 'still valid', management maintains.